Halozyme Therapeutics, Inc. HALO

P/E (TTM)

27.93

Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.

Forward P/E

—

P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.

EPS (TTM)

$2.56

Diluted earnings per share over the trailing twelve months.

Beta

0.90

Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.

Dividend Yield

—

Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.

Profit Margin

24.9%

Net income divided by revenue. Comparable within a sector, less so across sectors.

52w range

$61.23 – $104.78

Lowest and highest closing prices over the past 52 weeks.

Analyst Target

—

Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $11.6B · P/B 162.13 · P/S 6.94.